$CVM
CEL SCI CORP Stock $cvm

$cvm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000165495424006411 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.967M	$2.447M
YoY Change	-19.84%	16.95%
% of Gross Profit
Research & Development	$4.703M	$4.629M
YoY Change	-17.89%	-23.92%
% of Gross Profit
Depreciation & Amortization	$984.2K	$988.8K
YoY Change	-0.15%	0.34%
% of Gross Profit
Operating Expenses	$6.670M	$7.076M
YoY Change	-18.47%	-13.46%
Operating Profit	-$6.670M	-$7.076M
YoY Change	-18.47%	-13.46%
Interest Expense	-$190.7K	-$182.7K
YoY Change	4.97%	14.86%
% of Operating Profit
Other Income/Expense, Net	$4.380K	$13.76K
YoY Change	-213.77%	-283.47%
Pretax Income	-$6.857M	-$7.245M
YoY Change	-18.06%	-13.16%
Income Tax
% Of Pretax Income
Net Earnings	-$6.857M	-$7.245M
YoY Change	-18.06%	-13.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.14	-$0.14
COMMON SHARES
Basic Shares Outstanding	54.16M shares	50.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$435.8K	$5.325M
YoY Change	-91.55%	-47.18%
Cash & Equivalents	$384.7K	$5.309M
Short-Term Investments	$51.13K	$16.13K
Other Short-Term Assets	$551.3K	$696.7K
YoY Change	19.12%	16.42%
Inventory	$2.555M	$2.489M
Prepaid Expenses	$551.3K	$696.6K
Receivables
Other Receivables
Total Short-Term Assets	$3.542M	$8.511M
YoY Change	-54.18%	-32.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.613M	$9.113M
YoY Change	-19.31%	-18.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.391M	$2.393M
YoY Change	-0.37%	-1.17%
Total Long-Term Assets	$20.53M	$21.54M
YoY Change	-16.52%	-15.94%
TOTAL ASSETS
Total Short-Term Assets	$3.542M	$8.511M
Total Long-Term Assets	$20.53M	$21.54M
Total Assets	$24.07M	$30.05M
YoY Change	-25.53%	-21.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.369M	$1.016M
YoY Change	-21.42%	-46.21%
Accrued Expenses	$1.272M	$1.219M
YoY Change	11.47%	14.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.949M	$1.889M
YoY Change	13.46%	18.05%
Total Short-Term Liabilities	$5.506M	$5.087M
YoY Change	4.04%	-4.23%
LONG-TERM LIABILITIES
Long-Term Debt	$8.478M	$8.987M
YoY Change	-18.54%	-17.21%
Other Long-Term Liabilities	$125.0K	$125.0K
YoY Change	0.0%	0.0%
Total Long-Term Liabilities	$125.0K	$125.0K
YoY Change	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.506M	$5.087M
Total Long-Term Liabilities	$125.0K	$125.0K
Total Liabilities	$15.60M	$15.74M
YoY Change	-11.03%	-12.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$507.9M	-$501.0M
YoY Change	5.93%	6.36%
Common Stock	$542.6K	$540.8K
YoY Change	21.25%	23.51%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.473M	$14.30M
YoY Change
Total Liabilities & Shareholders Equity	$24.07M	$30.05M
YoY Change	-25.53%	-21.33%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$6.857M	-$7.245M
YoY Change	-18.06%	-13.16%
Depreciation, Depletion And Amortization	$984.2K	$988.8K
YoY Change	-0.15%	0.34%
Cash From Operating Activities	-$4.579M	-$4.528M
YoY Change	-19.19%	-39.4%
INVESTING ACTIVITIES
Capital Expenditures	$23.47K	$0.00
YoY Change	-88.08%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$23.47K	$0.00
YoY Change	-88.08%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-322.3K	6.596M
YoY Change	-133.87%	-1798.36%
NET CHANGE
Cash From Operating Activities	-4.579M	-4.528M
Cash From Investing Activities	-23.47K	0.000
Cash From Financing Activities	-322.3K	6.596M
Net Change In Cash	-4.925M	2.068M
YoY Change	0.27%	-125.94%
FREE CASH FLOW
Cash From Operating Activities	-$4.579M	-$4.528M
Capital Expenditures	$23.47K	$0.00
Free Cash Flow	-$4.602M	-$4.528M
YoY Change	-21.5%	-40.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	9949565	usd
CY2024Q1	us-gaap	Assets Assets	30048105	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1015969	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5087017	usd
CY2024Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	8987319	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1544126	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1652949	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	usd
CY2023Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	125000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	17313360	usd
CY2023Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2009786	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	5585846	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	51650	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13211	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-64861	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12730000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	447291	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-322942	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	696648	usd
CY2024Q1	us-gaap	Liabilities Liabilities	15743462	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	540837	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	474223	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	514809617	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	499832063	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000725363
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54083718	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47422304	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	0	shares
	cvm	Net Of Discount NetOfDiscount	11900000.0	usd
CY2024Q1	cvm	Operating Lease Weighted Average Remaining Lease Term One OperatingLeaseWeightedAverageRemainingLeaseTermOne	P4Y7M2D
CY2023Q1	cvm	Weighted Average Number Of Share Outstanding Basics And Diluted WeightedAverageNumberOfShareOutstandingBasicsAndDiluted	45581381	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-11889
	dei	Entity Registrant Name EntityRegistrantName	CEL-SCI CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	CO
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-0916344
	dei	Entity Address Address Line1 EntityAddressAddressLine1	8229 Boone Boulevard
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 802
	dei	Entity Address City Or Town EntityAddressCityOrTown	Vienna
	dei	Entity Address State Or Province EntityAddressStateOrProvince	VA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	22182
	dei	City Area Code CityAreaCode	703
	dei	Local Phone Number LocalPhoneNumber	506-9460
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	CVM
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54159937	shares
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5309321	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4145735	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	520368	usd
CY2024Q1	cvm	Supplies Used For Rd And Manufacturing Current SuppliesUsedForRDAndManufacturingCurrent	2489284	usd
CY2023Q3	cvm	Supplies Used For Rd And Manufacturing Current SuppliesUsedForRDAndManufacturingCurrent	2248072	usd
CY2024Q1	us-gaap	Deposits Assets Current DepositsAssetsCurrent	16129	usd
CY2023Q3	us-gaap	Deposits Assets Current DepositsAssetsCurrent	4245	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	8511382	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	6918420	usd
CY2024Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	8251453	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	9131987	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1598879	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1698243	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9113284	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10188126	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	180482	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	197704	usd
CY2024Q1	us-gaap	Deposits Assets DepositsAssets	2319101	usd
CY2023Q3	us-gaap	Deposits Assets DepositsAssets	2319101	usd
CY2024Q1	cvm	Supplies Used For Rd And Manufacturing Non Current SuppliesUsedForRDAndManufacturingNonCurrent	73524	usd
CY2023Q3	cvm	Supplies Used For Rd And Manufacturing Non Current SuppliesUsedForRDAndManufacturingNonCurrent	74669	usd
CY2023Q3	us-gaap	Assets Assets	30528250	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1219399	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1049581	usd
CY2024Q1	cvm	Due To Employee Current DueToEmployeeCurrent	751607	usd
CY2023Q3	cvm	Due To Employee Current DueToEmployeeCurrent	557244	usd
CY2024Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1888767	usd
CY2023Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	1771804	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	211275	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	197431	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	600000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54083718	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47422304	shares
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-501045811	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-487091396	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	14304643	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13214890	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30048105	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30528250	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8981044	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11476034	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4580791	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4350761	usd
	us-gaap	Operating Expenses OperatingExpenses	13561835	usd
	us-gaap	Operating Expenses OperatingExpenses	15826795	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13561835	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15826795	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	380397	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	311852	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	12183	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	57671	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13954415	usd
	us-gaap	Net Income Loss NetIncomeLoss	-16196318	usd
	cvm	Modification Of Warrants ModificationOfWarrants	0	usd
	cvm	Modification Of Warrants ModificationOfWarrants	-171552	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13954415	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16367870	usd
	cvm	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.28
	cvm	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.38
	cvm	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	50228860	shares
	cvm	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	43513571	shares
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4628535	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6083488	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2447413	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2092758	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	7075948	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	8176246	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7075948	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8176246	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	182701	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	159063	usd
CY2024Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	13758	usd
CY2023Q1	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	7500	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7244891	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8342809	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7244891	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8342809	usd
CY2024Q1	cvm	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.14
CY2023Q1	cvm	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.19
CY2024Q1	cvm	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	52006442	shares
CY2023Q1	cvm	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	43588381	shares
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	13214890	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	48907	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	202307	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4980000	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1383909	usd
CY2023Q4	cvm	Share Issuance Costs ShareIssuanceCosts	-470229	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-6709524	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12650260	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	53485	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	380870	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7750000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1432540	usd
CY2024Q1	cvm	Share Issuance Costs ShareIssuanceCosts	-717621	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-7244891	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	14304643	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	32163207	usd
CY2022Q4	cvm	Warrant Exercises Amount WarrantExercisesAmount	447291	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1703931	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	50178	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	91623	usd
CY2022Q4	cvm	Incentive Stock Forfeited Amount IncentiveStockForfeitedAmount	-11100	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-7853509	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	26591621	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1743288	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	54865	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	100635	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8342809	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	20147600	usd
	us-gaap	Profit Loss ProfitLoss	-13954415	usd
	us-gaap	Profit Loss ProfitLoss	-16196318	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1993395	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1973982	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	4383	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	9545	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	547893	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	285722	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2816449	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3436119	usd
	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	102392	usd
	cvm	Common Stock Contributed To Employee Benefit Plan CommonStockContributedToEmployeeBenefitPlan	105043	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-30996	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	180222	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	240067	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	170434	usd
	cvm	Increase Decrease In Deposit Assets IncreaseDecreaseInDepositAssets	-11884	usd
	cvm	Increase Decrease In Deposit Assets IncreaseDecreaseInDepositAssets	-2354723	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-896939	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	102841	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	59818	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	111515	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	194363	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	37798	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9415608	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12137820	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	165032	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-165032	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1218937	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9010	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	867008	usd
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	761223	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10644055	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1163586	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-12625794	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4145735	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22672138	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5309321	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10046344	usd
	cvm	Property And Equipment Purchases Included In Current Liabilities PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities	0	usd
	cvm	Property And Equipment Purchases Included In Current Liabilities PropertyAndEquipmentPurchasesIncludedInCurrentLiabilities	176743	usd
	cvm	Assets Purchased Under Finance Leases AssetsPurchasedUnderFinanceLeases	20797	usd
	cvm	Assets Purchased Under Finance Leases AssetsPurchasedUnderFinanceLeases	0	usd
	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	522	usd
	cvm	Finance Lease Obligation Included In Accounts Payable FinanceLeaseObligationIncludedInAccountsPayable	1402	usd
	cvm	Consulting Services Paid With Issuance Of Common Stock ConsultingServicesPaidWithIssuanceOfCommonStock	583177	usd
	cvm	Consulting Services Paid With Issuance Of Common Stock ConsultingServicesPaidWithIssuanceOfCommonStock	192258	usd
	cvm	Accrued Consulting Services To Be Paid With Common Stock AccruedConsultingServicesToBePaidWithCommonStock	165000	usd
	cvm	Accrued Consulting Services To Be Paid With Common Stock AccruedConsultingServicesToBePaidWithCommonStock	165000	usd
	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	46616	usd
	cvm	Financing Costs Included In Current Liabilities FinancingCostsIncludedInCurrentLiabilities	0	usd
	us-gaap	Interest Paid Net InterestPaidNet	480044	usd
	us-gaap	Interest Paid Net InterestPaidNet	547765	usd
	cvm	Impairment Of Long Lived Assets Policy Textblock ImpairmentOfLongLivedAssetsPolicyTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Impairment of long-lived assets</em> – CEL-SCI’s fixed assets are made up of leasehold improvements, furniture, and equipment. ASC 360-10 requires that a long-lived asset group be reviewed for impairment only when events or changes in circumstances indicate that the carrying amount of the long-lived asset (group) might not be recoverable. CEL-SCI’s recurring losses are a triggering event that could indicate impairment of long-lived assets such as fixed assets. CEL-SCI reviews these assets to determine if events or changes in circumstances indicate the existence of impairment. If indicators of impairment exist, the Company tests for recoverability, then, if necessary, measures and records the impairment. The amount of the impairment loss would be the amount by which the carrying amount of the asset (group) exceeds its fair value.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><em>Use of Estimates</em> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying disclosures. These estimates are based on management’s best knowledge of current events and actions the Company may undertake in the future. Estimates are used in accounting for, among other items, inventory obsolescence, accruals, stock options, useful lives for depreciation and amortization of long-lived assets, right of use assets and lease liabilities, deferred tax assets and the related valuation allowance. Actual results could differ from estimates, although management does not generally believe such differences would materially affect the financial statements in any given year. Additionally, in calculating the right of use assets and lease liabilities, estimates and assumptions were used to determine the incremental borrowing rates and the expected lease terms. The Company considers the estimates used in valuing the stock options and the lease assets and liabilities to be significant.</p>
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	138400	shares
CY2024Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	234332	usd
CY2023Q4	cvm	Incremental Cost Deemed Dividend IncrementalCostDeemedDividend	172000	usd
	cvm	Net Of Discount NetOfDiscount	1190000	usd
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.03	pure
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1300000	usd
CY2024Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0846	pure
	cvm	Finance Lease Weighted Average Remaining Lease Term One FinanceLeaseWeightedAverageRemainingLeaseTermOne	P4Y7M2D
	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd

Files In Submission

Name	View Source	Status
0001654954-24-006411-index-headers.html	Edgar Link	pending
0001654954-24-006411-index.html	Edgar Link	pending
0001654954-24-006411.txt	Edgar Link	pending
0001654954-24-006411-xbrl.zip	Edgar Link	pending
cvm-20240331.xsd	Edgar Link	pending
cvm-20240331_def.xml	Edgar Link	unprocessable
cvm-20240331_lab.xml	Edgar Link	unprocessable
cvm_10q.htm	Edgar Link	pending
cvm_10qimg10.jpg	Edgar Link	pending
cvm_10qimg11.jpg	Edgar Link	pending
cvm_10qimg12.jpg	Edgar Link	pending
cvm_10qimg13.jpg	Edgar Link	pending
cvm_10qimg14.jpg	Edgar Link	pending
cvm_10qimg8.jpg	Edgar Link	pending
cvm_10qimg9.jpg	Edgar Link	pending
cvm_ex31.htm	Edgar Link	pending
cvm_ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
cvm_10q_htm.xml	Edgar Link	completed
cvm-20240331_cal.xml	Edgar Link	unprocessable
cvm-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVM
CEL SCI CORP Stock $cvm

2024 Q2 Form 10-Q Financial Statement

#000165495424006411 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM CEL SCI CORP Stock $cvm

2024 Q2 Form 10-Q Financial Statement

#000165495424006411 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVM
CEL SCI CORP Stock $cvm